A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke

This study tests the drug, Plasmin (Human), in patients with a stroke due to a clot in the middle cerebral artery (MCA). Plasmin is an enzyme that causes clot lysis by cleaving a clot component, fibrin. In this study, Plasmin (Human) is administered locally through a catheter to the clot within 9 hours of the stroke onset. Three doses of Plasmin (Human) (20 mg, 40 mg, and 80 mg) are being tested in 3 different groups of patients. Patients are monitored by imaging of the affected artery and functional testing.

开始日期2009-11-01

申办/合作机构

Grifols Therapeutics, Inc.

NCT00418483

/ Completed临床1期

A Sequential Phase I/II Dose Escalation and Dose Selection Safety Study of Regional Intra-thrombus Plasmin (Human) Infusion In Acute Lower Extremity Native Artery or Bypass Graft Occlusion

The purpose of this study is to evaluate the safety of increasing doses of intra-thrombus Plasmin (Human) in acute peripheral arterial occlusion (aPAO). The ability of these Plasmin doses to dissolve the clots will be estimated by arteriography.

开始日期2007-03-01

申办/合作机构

Grifols Therapeutics, Inc.

100 项与 Human plasma-derived fibrinolysin (Grifols) 相关的临床结果

登录后查看更多信息

100 项与 Human plasma-derived fibrinolysin (Grifols) 相关的转化医学

登录后查看更多信息

100 项与 Human plasma-derived fibrinolysin (Grifols) 相关的专利（医药）

登录后查看更多信息

356

项与 Human plasma-derived fibrinolysin (Grifols) 相关的文献（医药）

2026-04-01·NEUROSCIENCE LETTERS

Plasmin contributes to arthritis pain by cleaving proteinase activated receptor-4 in rats

Article

作者: McDougall, Jason J

Proteinase activated receptors (PARs) are family of four G protein-coupled receptors that signal following enzymatic cleavage of their extracellular N-terminal domain. Activation of PAR-4 has been found to sensitize joint nociceptors leading to the generation of pain. The identity of the proteinases that activate PAR-4 in joints is unclear but may include the serine proteinase plasmin. The aim of this study was to determine whether plasmin signals joint pain via PAR-4 activation and whether the plasmin inhibitor neuroserpin could attenuate acute inflammatory joint pain. Either plasmin (0.04 - 04U) or vehicle (0.9% saline) were injected into the right knee joint of male rats and pain behaviour was assessed by von Frey hair mechanosensitivity or hindlimb dynamic weight bearing. Intra-articular injection of plasmin increased hindpaw mechanosensitivity and reduced the amount of weight borne on the ipsilateral hindlimb. These pain behaviours were attenuated by pre-treating the rats with the PAR-4 antagonist pepducin P4pal10 (100 μg i.p.) or the plasmin inhibitor neuroserpin (3 μg s.c.). In a group of animals with acute synovitis, prophylactic treatment with neuroserpin increased von Frey hair mechanical threshold but had no effect on weight bearing deficits. Taken together, these data show that plasmin produces joint pain by local activation of PAR-4 while blockade of plasmin bioactivity with neuroserpin can alleviate joint pain in an acute model of arthritis.

2026-01-28·INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Enzymatic Disruption of the Internal Limiting Membrane Enhances Transplanted Retinal Ganglion Cell Survival

Article

作者: Rao, Mishal ; Lo, Jung ; Stavropoulos, Dimitrios ; Wang, Shining ; Lin, Ya-Ling ; Zhao, Chengcheng ; Pi, Shaohua ; Mirzaliyeva, Laman ; Sahel, José-Alain ; Johnson, Thomas V. ; Chen, Chi-Yu ; Liu, Chia-Chun ; Rosin, Boris ; Talebian, Niki ; Chang, Kun-Che

Purpose:

In mammals, retinal ganglion cells (RGCs) lack the ability to regenerate after injury, and RGC transplantation is a potential approach for cell replacement therapy. However, the internal limiting membrane (ILM) in the retina serves as a significant barrier to donor cell integration, highlighting the need for strategies to disrupt it. We hypothesize that plasmin can enzymatically disrupt the ILM, thereby enhancing the survival of transplanted donor RGCs.

Methods:

In vivo, 8- to 10-week-old mice were intravitreally injected with phosphate-buffered saline (PBS) or plasmin (2.3 or 4.6 µg). Immunohistology was performed to verify ILM disruption and assess microglial reactivity and RGC survival. Hematoxylin and eosin (H&E) staining was used to evaluate immune cell infiltration in the vitreous, electrophysiology to assess retinal function, and optical coherence tomography to evaluate retinal structure. Donor RGCs were obtained by differentiating human embryonic stem cells into retinal organoids (ROs). The RO-derived RGCs were transplanted into plasmin-treated eyes 2 weeks after plasmin treatment. Transplanted RGCs were identified using tdTomato fluorescence.

Results:

Our study identified the optimal dose of plasmin (2.3 µg) that effectively disrupts the ILM without triggering microglia reactivity or immune infiltration in the vitreous. In addition, neither the RGC number nor RGC function was affected after plasmin treatment, whereas increased survival of transplanted cells was observed in the plasmin-treated retinas.

Conclusions:

Our findings provide a translational insight on plasmin-mediated ILM disruption, demonstrating that an optimal dose can effectively degrade the mouse ILM without compromising RGC integrity, offering a promising strategy to enhance transplanted cells' survival.

2025-04-01·CYTOTHERAPY

Robust differentiation and potent immunomodulation of human mesenchymal stromal cells cultured with a xeno-free GMP protein supplement

Article

作者: Seriola, Anna ; Belda, Francisco ; Ojosnegros, Samuel ; Oliver-Vila, Irene ; Sesma-Herrero, Eduardo

BACKGROUND/AIMS:

Human mesenchymal stromal cells (hMSC) are multipotent adult cells commonly used in regenerative medicine as advanced therapy medicinal products. The expansion of these cells in xeno-free supplements is highly encouraged by regulatory agencies due to safety concerns. However, the number of supplements with robust performance and consistency for hMSC expansion are limited. Here, we evaluate a xeno-free human plasma-derived protein supplement (Plastem, Grifols) for the expansion and functional evaluation of hMSCs.

METHODS:

hMSC from bone marrow, adipose tissue and umbilical cord were obtained from two suppliers and cultured in Dulbecco's modified Eagle's medium (DMEM/F-12) supplemented with fetal bovine serum 10% (FBS), human platelet lysate 5% (hPL) or Plastem 10%+ hPL0.5%. Cell proliferation was evaluated after culturing hMSC for 13 days with trypan blue exclusion. hMSC immunophenotype was assessed by flow cytometry of surface markers expression. Multipotentiality assay determined the ability of hMSC to differentiate into osteogenic, chondrogenic and adipogenic lineages after 21 days, by using specific staining. Immunomodulatory properties of hMSC were analyzed by measuring suppression of human peripheral blood mononuclear cell (PBMC) proliferation in co-culture with hMSC.

RESULTS:

Plastem 10% + hPL 0.5% supported robust and sustained hMSC growth with a similar efficiency to the reference supplement FBS 10%. hMSC cultured with the xeno-free supplement presented a similar morphology comparable to FBS-supplemented cells and maintained typical expression of markers: positive (>95%) for CD90, CD73 and CD105; and negative (<5%) for CD45, CD14, CD19, CD34 and HLA-DR. Likewise, hMSC showed potent, in vitro differentiation potential into osteogenic, chondrogenic and adipogenic lineages, outperforming the results obtained with traditional reference supplements in several instances. They retained their immunomodulatory properties, inhibiting the proliferation of phytohemagglutinin (PHA)-stimulated PBMCs with a notable enhancement of the immunomodulatory capacity of hMSCs compared to conventional reference supplements.

CONCLUSIONS:

Plastem allowed hMSC expansion while preserving phenotype and showed remarkable differentiation and immunomodulatory properties, supporting its use for cell therapy manufacturing processes as a robust, xeno-free alternative to FBS and hPL. Moreover, Plastem can be manufactured at an industrial level, making it a scalable solution for widespread application.

项与 Human plasma-derived fibrinolysin (Grifols) 相关的新闻（医药）

2025-11-18

·grifols.com

Grifols receives expanded indication for THROMBATE III® (antithrombin III [human]) label in U.S., strengthening treatment options for pediatric patients

The information is aimed exclusively at authorized healthcare professionals to prescribe or supply medical products and its correct interpretation requires specialized training. Are you a healthcare professional? THROMBATE III is now the only antithrombin concentrate (ATc) approved for hereditary antithrombin deficiency (hATd) in both adult and pediatric patients FDA approval was based on submitted data extrapolation from two clinical trials in adult patients addressing critical gaps in the clinical comprehension and treatment of pediatric hATd The expanded label for THROMBATE III indicates it can be safely and effectively used in pediatric patients with hATd, a rare patient population Barcelona, Spain, November 18, 2025 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that the United States Food and Drug Administration (FDA) has approved an expanded indication for THROMBATE III®, the company’s antithrombin III [human concentrate], to include pediatric patients diagnosed with hereditary antithrombin deficiency (hATd). With this expansion, THROMBATE III becomes the first and only antithrombin concentrate (ATc) approved for adults and pediatrics with hATd, a frequently undiagnosed blood clotting disorder that may affect up to 700,000 people in the U.S. People with this condition have a higher-than-average risk of developing abnormal blood clots. Considering that hATd has one of the highest thrombotic risks of all of the inherited thrombophilias1 and 85% of patients with hATd will have at least one thrombotic episode by age 502, this approval represents a significant step forward for patients and families impacted by hATd. “This label expansion helps close a long-standing gap in the treatment of pediatric patients with hereditary antithrombin deficiency,” said George M. Rodgers, III, M.D., Ph.D., Professor of Medicine in the Division of Hematology and Hematologic Malignancies at the University of Utah School of Medicine. “It gives clinicians added confidence that ATc can be appropriately used in children.” FDA approval was supported by the extrapolation of data from two clinical studies in adult patients, concluding that ATc – which has been successfully used for treatment in adults with hATd for over three decades – can be safely and effectively used in pediatric patients with hATd. “Expanding the indication to include pediatric patients provides a new option for children and families facing hereditary antithrombin deficiency,” said Roland Wandeler, president of Grifols Biopharma. “This is another example of Grifols’ continuing work to provide more patients with medicines to enhance their health and well-being.” Treatment and prevention of thromboembolism in patients with hATd typically requires anticoagulation, with replacement of antithrombin (AT) with antithrombin sources like ATc or fresh frozen plasma (FFP) administration in certain high-risk situations. THROMBATE III has been approved in the U.S. for treatment of adults with hATd since 1991. About THROMBATE III® Clinical studies have shown that THROMBATE III is an effective choice for patients with hereditary antithrombin deficiency (hATd) and for the treatment and prevention of thromboembolism, including before, during, and after surgery and childbirth. THROMBATE III (antithrombin III [human]) is indicated in adult and pediatric patients with hereditary antithrombin deficiency for treatment and prevention of thromboembolism and for prevention of perioperative and peripartum thromboembolism. Important Safety Information Hypersensitivity reactions may occur. Should evidence of an acute hypersensitivity reaction be observed, promptly interrupt the infusion and begin appropriate treatment. Because THROMBATE III is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. There is also the possibility that unknown infectious agents may be present in the product. Perform coagulation tests to avoid excessive or insufficient anticoagulation and monitor for bleeding or thrombosis. Measure functional plasma AT levels with amidolytic or clotting assays; do not use immunoassays. In clinical studies, the most common adverse reactions (≥ 5% of patients) were dizziness, chest discomfort, nausea, dysgeusia, and pain (cramps). The anticoagulant effect of heparin is enhanced by concurrent treatment with THROMBATE III in patients with hereditary AT deficiency. Thus, in order to avoid bleeding, the dosage of heparin (or low molecular weight heparin) may need to be reduced during treatment with THROMBATE III. Please see accompanying full Prescribing Information for THROMBATE III®. Product information, including indications, safety warnings, and prescribing details, may vary by country. For information specific to your region, please consult your local regulatory authority or healthcare provider. 1 Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia. 2008;14(6):1229-1239 2 Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med. 2002;126(11):1326-1336 Our media relations team can be reached at: (+34) 93 571 00 02 media@grifols.com. Restricted to media inquiries only. For general questions and requests, please contact corporatecomms@grifols.com.

上市批准

2025-11-17

·EINPresswire

Albumin Market Size Set for Rapid Expansion, Valued at USD 8.95 Billion by 2030 Driven by Impressive 6.4% CAGR

Significant surge in non-therapeutic application of albumin, increasing production of immunoglobulins & plasma collection is expected to drive the growth PORTLAND, OR, UNITED STATES, November 17, 2025 / EINPresswire.com / -- The prevalence of diseases and life-threatening conditions such as hypoalbuminemia, burns, trauma, liver cirrhosis, and cardiac surgeries significantly propel the growth of the albumin market. The surge in shock and burn cases is anticipated to drive demand for albumin, particularly as a vital volume expander during burn shock resuscitation and for correcting hypoalbuminemia. According to the World Health Organization (WHO), an alarming statistic reveals that approximately 11 million individuals endure burn wounds annually. This underscores the critical role albumin plays in addressing the medical consequences of such incidents. The market's growth is closely tied to its indispensability in therapeutic interventions, especially in scenarios involving trauma, burns, and shock, highlighting its crucial role in modern healthcare. Allied Market Research has published a study report with the title Albumin Market Size was Valued at ๐๐๐ ๐.๐๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ข๐ง ๐๐๐๐, and is Anticipated to Garner ๐๐๐ ๐.๐๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐ฒ ๐๐๐๐, registering a ๐๐๐๐ ๐จ๐ ๐.๐% from 2021 to 2030. The report provides an extensive analysis of changing market dynamics, major segments, value chain, competitive scenario, and regional landscape. This research offers a valuable guidance to leading players, investors, shareholders, and startups in devising strategies for sustainable growth and gaining competitive edge in the market. ๐๐๐ญ ๐๐๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐ฐ๐ข๐ญ๐ก ๐๐ซ๐๐ฉ๐ก๐ฌ ๐๐ง๐ ๐๐ข๐ ๐ฎ๐ซ๐๐ฌ ๐๐๐ซ๐: https://www.alliedmarketresearch.com/request-sample/2583 ๐๐จ๐ฉ ๐๐ฅ๐๐ฎ๐ฆ๐ข๐ง ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ โข Takeda Pharmaceuticals Inc โข Thermo Fisher Scientific โข Ventria Bioscience โข Baxter International Inc. โข China Biologic Products, Inc. โข Merck KGaA โข Novozymes โข Octapharma AG โข CSL Limited โข Grifols, S.A. ๐๐ฅ๐๐ฎ๐ฆ๐ข๐ง ๐๐๐ซ๐ค๐๐ญ ๐๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง: - The global albumin market is analysed across type, application and region. By type, the human serum albumin segment dominated the market in 2022, accounting for almost two-thirds of the global albumin market and is expected to register highest CAGR of 6.5% during the forecast period owing to the widespread use and diverse applications of human serum albumin in various medical interventions. As a critical component of blood plasma, human serum albumin finds extensive utilization in therapeutic treatments, including fluid resuscitation, wound healing, and the management of hypoalbuminemia. Its compatibility. By application, the therapeutics segment dominated the market in 2022, accounting two-fifths of the global albumin market and is expected to register highest CAGR of 6.7% during the forecast period. This is attributed to the increasing recognition of albumin's therapeutic benefits across diverse medical applications. Its role in addressing critical health challenges such as liver diseases, trauma, and surgical interventions and ability to maintain fluid balance, transport crucial substances, and mitigate protein deficiencies underscores its significance in therapeutic treatments. In addition, ongoing R&D efforts continue to unveil new therapeutic applications for albumin, further propelling its demand. By sales channel, the B2B segment dominated the market in 2022, accounting almost three-fifths of the global albumin market, owing to increased collaborations and partnerships among pharmaceutical and biotech companies. The B2B model facilitates bulk purchases, ensuring a steady supply of albumin for research, manufacturing, and development activities, thus driving market growth.โฏHowever, the B2C segment is expected to register highest CAGR of 6.7% during the forecast period owing to direct sale of products from a business (such as pharmaceutical and biotech companies) to individual consumers or end-users. This approach enhances market accessibility, fosters customer engagement, and potentially leads to increased sales and market share, as businesses establish direct connections with end-users in the dynamic albumin market.โฏ By region, North America held the highest market share in terms of revenue in 2022, accounting for more than two-fifths of the global albumin market revenue, owing to growing access to advanced technologies and a well-developed network of healthcare & research facilities. In addition, the growing aging population and high incidence of diseased conditions owing to surgical interventions, contribute to the sustained demand for albumin products. However, the Asia-Pacific segment is projected to register highest CAGR of 7.0% during the forecast period owing to increasing healthcare infrastructure development, rising awareness about albumin applications, a surge in surgical procedures, and growing initiatives taken by key players by adopting new strategies. ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐ญ๐ก๐ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.alliedmarketresearch.com/purchase-enquiry/2583 Key Findings of The Study โข By type, the human serum albumin segment was the highest contributor to the market in 2020. โข On the basis of application type, the therapeutics segment dominated the market in 2020, and is expected to continue this trend during the forecast period. โข Region-wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period. ๐๐ฎ๐ซ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง ๐๐ซ๐จ๐ฏ๐ข๐๐๐ฌ ๐๐จ๐ฎ ๐๐ง๐ฌ๐ฐ๐๐ซ ๐ญ๐จ ๐๐๐ฅ๐จ๐ฐ ๐๐๐ง๐ญ๐ข๐จ๐ง๐๐ ๐๐ฎ๐๐ฌ๐ญ๐ข๐จ๐ง: โข Which are the driving factors responsible for the growth of market? โข Which are the roadblock factors of this market? โข What are the new opportunities, by which market will grow in coming years? โข What are the trends of this market? โข Which are main factors responsible for new product launch? โข How big is the global & regional market in terms of revenue, sales and production? โข How far will the market grow in forecast period in terms of revenue, sales and production? โข Which region is dominating the global market and what are the market shares of each region in the overall market in 2022? โข How will each segment grow over the forecast period and how much revenue will these segments account for in 2030? โข Which region has more opportunities? ๐๐ฒ ๐๐๐ ๐ข๐จ๐ง ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค โข North America (U.S., Canada, Mexico) โข Europe (Germany, France, UK, Italy, Spain, Rest of Europe) โข Asia-Pacific (Japan, China, India, Rest of Asia-Pacific) โข LAMEA (Brazil, Saudi Arabia, South Africa, Rest of LAMEA) ๐๐จ๐ง๐ญ๐๐๐ญ ๐๐๐ญ๐๐ข๐ฅ๐ฌ: David Correa USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022 help@alliedmarketresearch.com ๐๐๐จ๐ฎ๐ญ ๐๐ฌ Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. David Correa Allied Market Research + 1 800-792-5285 email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-04-08

·Business Wire

IBL International collaborates with Grifols on advanced biomarker panels

MÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a global healthcare company and leading producer of plasma-derived medicines and innovative diagnostic solutions, to transform the specialty diagnostics market. Under this collaboration, IBL will develop biomarker panels for specialty diagnostics based on Grifols’ random access, single molecule counting (SMC) platform. These panels will address key customer needs in specialty diagnostics, offering solutions for laboratories and patients alike. The agreement includes a framework for product development, manufacturing and commercialization, ensuring a reliable and efficient delivery to the market. The project brings together IBL’s expertise in specialty diagnostic assay development and Grifols’ leadership in diagnostic instrumentation to produce a state-of-the-art system. The collaboration encompasses: Development of biomarker panels by IBL, tailored for random access on the SMC Platform. Manufacturing and supply of these products by IBL under a master supply agreement. Achieving better specialty diagnostics Specialty diagnostics are often performed outside the high-throughput, automated workflows of the core laboratory, requiring specialized equipment and processes to handle low-volume, high-value tests. This partnership streamlines these processes by combining multiple specialty diagnostic parameters into a single workflow. Grifols’ random access technology allows laboratories to process tests as soon as samples arrive, eliminating delays associated with batching and enabling faster, more efficient diagnostics that enhance patient care. “Partnering with Grifols allows us to scale healthcare innovation globally,” said Mukta Acharya, Head of Tecan’s Life Sciences Business. “By leveraging IBL’s entrepreneurial spirit and technological expertise, we’re addressing unmet needs in specialty diagnostics. Together, we’re creating solutions that empower laboratories and enhance patient journeys with reliable and sensitive diagnostics.” “Our collaboration with IBL demonstrates our commitment to our strategic plan for developing innovative clinical diagnostic solutions,” added Guillermo Marco-Gardoqui, SVP Diagnostic Operations and Strategy at Grifols. “By integrating IBL’s biomarker panels with the advanced capabilities of the SMC Platform, we are enhancing clinical workflows and addressing critical gaps in patient care.” Driving innovation The panels under development respond to customer feedback, ensuring they meet the needs of both laboratories and patients. This first-in-class random access system with SMC technology introduces a clinical market solution that integrates seamlessly into the core lab, enhancing workflow efficiency and allowing for ultra-highly sensitive, multiplexed assays. The partnership demonstrates Tecan’s commitment to improving people’s lives and health by enabling customers to scale healthcare innovation globally. It highlights IBL’s leading position in specialty diagnostics and reflects Tecan’s commitment to advancing modern, multiplexed diagnostic solutions.

诊断试剂

100 项与 Human plasma-derived fibrinolysin (Grifols) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
动脉闭塞	临床2期	美国	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	比利时	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	保加利亚	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	捷克	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	德国	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	印度	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	秘鲁	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	波兰	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	罗马尼亚	Grifols Therapeutics, Inc.	2010-12-01
动脉闭塞	临床2期	塞尔维亚	Grifols Therapeutics, Inc.	2010-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01222117 (Pubmed)	临床2期	动脉闭塞	174	150 mg plasmin without BOC	選蓋廠糧艱鬱餘網網壓(廠願網壓齋顧鏇獵構製) = 積廠簾獵糧鬱遞憲願鏇鹽糧壓簾簾築憲蓋製願 (願廠願網糧餘鹹願鹹餘 ) 更多	-	2019-01-01
				rtPA without BOC	醖顧窪襯壓夢壓淵醖獵(獵鏇蓋網醖築廠壓蓋範) = 鏇鏇鹽獵選獵鏇鬱簾夢繭醖壓鬱遞醖獵鬱鏇範 (築餘蓋襯鑰簾糧餘簾鹹 ) 更多
NCT01014975 (CTgov)	临床1/2期	大脑中动脉梗塞 \| 急性缺血性卒中	40	Plasmin (Human) (20 mg Plasmin (Human))	鹹餘衊糧鑰齋觸醖夢繭 = 壓齋鏇醖廠憲齋壓廠衊鏇膚淵廠襯鏇襯醖築遞 (鹽窪觸選顧餘鏇範蓋遞, 憲襯顧顧壓襯壓範蓋積 ~ 齋鹹簾鏇範顧鑰選淵製) 更多	-	2015-10-21
				Plasmin (Human) (40 mg Plasmin (Human))	鹹餘衊糧鑰齋觸醖夢繭 = 積網鏇網築餘衊廠鏇壓鏇膚淵廠襯鏇襯醖築遞 (鹽窪觸選顧餘鏇範蓋遞, 願夢衊鏇衊壓積夢積選 ~ 願鑰構淵積簾製鏇廠壓) 更多